IRIS
FACCHINETTI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.130
AS - Asia 812
EU - Europa 573
SA - Sud America 162
AF - Africa 37
Continente sconosciuto - Info sul continente non disponibili 2
Totale 2.716
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.104
SG - Singapore 391
CN - Cina 202
SE - Svezia 161
IE - Irlanda 132
BR - Brasile 123
IT - Italia 99
HK - Hong Kong 75
VN - Vietnam 62
DE - Germania 48
NL - Olanda 30
ZA - Sudafrica 29
GB - Regno Unito 22
AT - Austria 21
CA - Canada 17
ID - Indonesia 15
RU - Federazione Russa 15
TR - Turchia 15
IN - India 14
AR - Argentina 12
EC - Ecuador 10
BD - Bangladesh 9
JP - Giappone 9
FR - Francia 8
PL - Polonia 8
BE - Belgio 5
FI - Finlandia 5
MX - Messico 5
PY - Paraguay 5
CL - Cile 4
PK - Pakistan 4
AL - Albania 3
BO - Bolivia 3
ES - Italia 3
UA - Ucraina 3
VE - Venezuela 3
IL - Israele 2
IQ - Iraq 2
KE - Kenya 2
KH - Cambogia 2
XK - ???statistics.table.value.countryCode.XK??? 2
BB - Barbados 1
BZ - Belize 1
CH - Svizzera 1
CI - Costa d'Avorio 1
DK - Danimarca 1
GD - Grenada 1
IR - Iran 1
IS - Islanda 1
JO - Giordania 1
KR - Corea 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
MN - Mongolia 1
NP - Nepal 1
OM - Oman 1
PE - Perù 1
PR - Porto Rico 1
PT - Portogallo 1
QA - Qatar 1
RO - Romania 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TG - Togo 1
TN - Tunisia 1
UY - Uruguay 1
UZ - Uzbekistan 1
ZM - Zambia 1
Totale 2.716
Salva come PNG Salva come JPEG
Città #
Singapore 215
Chandler 195
Ashburn 167
Dublin 129
Dallas 105
Santa Clara 100
Hong Kong 74
New York 54
Beijing 50
Shanghai 49
Ann Arbor 35
Boardman 30
Johannesburg 25
Princeton 23
Ho Chi Minh City 21
Los Angeles 21
Bremen 20
Vienna 18
Columbus 14
Dearborn 14
Parma 14
Jakarta 13
Des Moines 12
Hanoi 11
Wilmington 11
Munich 10
Buffalo 9
São Paulo 9
The Dalles 9
Council Bluffs 8
Nanjing 8
Warsaw 8
Curitiba 7
Moscow 7
Pune 7
Tokyo 7
Changsha 6
London 6
Milan 6
Quito 6
Rio de Janeiro 6
Atlanta 5
Bologna 5
Brooklyn 5
Brussels 5
Chicago 5
Da Nang 5
Frankfurt am Main 5
Helsinki 5
Houston 5
Izmir 5
Nuremberg 5
Amsterdam 4
Ankara 4
Belo Horizonte 4
Busseto 4
Kunming 4
Nanchang 4
Pavia 4
Phoenix 4
San Jose 4
Toronto 4
Washington 4
Boston 3
Buenos Aires 3
Cape Town 3
Dhaka 3
Fremont 3
Grafing 3
Guangzhou 3
Haiphong 3
Hebei 3
Istanbul 3
Jinan 3
Marseille 3
Mexico City 3
Montreal 3
Nanning 3
Naples 3
Orem 3
Porto Alegre 3
Redondo Beach 3
Redwood City 3
Shenyang 3
Sumaré 3
Thái Bình 3
Tirana 3
Woodbridge 3
Alvorada 2
Baghdad 2
Biên Hòa 2
Bắc Ninh 2
Campinas 2
Candiac 2
Charlotte 2
Chennai 2
Ciudad del Este 2
Denver 2
Fairfield 2
Florence 2
Totale 1.737
Salva come PNG Salva come JPEG
Nome #
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 157
Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient 141
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 132
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 128
CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients 123
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib 115
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: A systematic review and meta-analysis 112
Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib 111
Vascular liver injury mimicking an intrahepatic cholangiocarcinoma in a COVID-19 patient 109
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination 107
Moving immune checkpoint blockade in thoracic tumors beyond NSCLC 106
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 106
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition 104
Cystic brain metastases and RET fusion in lung cancer 104
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib 103
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 101
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 99
Exploring the role of respiratory microbiome in lung cancer: A systematic review 95
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: A systematic review and meta-analysis 94
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 83
Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M? 83
Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC 75
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non–small Cell Lung Cancer 74
Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary? 52
Expert consensus on perioperative immunotherapy in non-small cell lung cancer: an editorial 51
Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis 36
A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020) 29
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 27
Multiple targets, germline BRCA1 mutation and HRD in a lung cancer patient: Molecular considerations and treatment decision-making 27
ALK fusions turn sixteen in lung cancer: a review on their biology, detection and therapy 24
Chasing EGFR Mutations in the Plasma of Patients With Resected NSCLC: Lessons in the ADAURA Era 18
Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in “PD-L1 Negative” NSCLC 18
Non-small-cell lung cancer: how to manage BRAF-mutated disease 16
Ad hoc afatinib in an eldery lung cancer patient with EGFR exon 19 deletion L747-A750>P 16
Totale 2.776
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.678
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.678
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202144 0 0 0 0 0 5 1 8 13 6 9 2
2021/2022150 2 2 0 29 2 3 27 7 9 6 7 56
2022/2023619 81 76 38 56 45 77 23 31 164 6 21 1
2023/2024229 11 19 3 2 17 80 18 17 12 10 10 30
2024/2025645 6 30 35 47 99 94 25 12 88 57 49 103
2025/2026913 132 91 215 166 298 11 0 0 0 0 0 0
Totale 2.776